Fewer shots for HPV protection? study tests 2-Dose vaccine schedule
NCT ID NCT05672927
Summary
This study aims to see if two doses of the approved 9-valent HPV vaccine provide similar protection against the virus as the standard three-dose schedule for women aged 27-45. Researchers will enroll 618 women who have never received the HPV vaccine and randomly assign them to receive either two or three doses over several months. The main goal is to compare the body's immune response (antibody levels) between the two groups over one year to determine if the shorter schedule is just as effective.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Medical Branch
RECRUITINGGalveston, Texas, 77555, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.